Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1975-7-1
pubmed:abstractText
6-N-Hydroxylaminopurine riboside (HAPR) was studied in man because of its therapeutic activity in several transplanted animal neoplasms. It was not cross-resistant to other antimetabolites useful in the treatment of human neoplasia. HAPR produced marked hemolytic anemia at doses far below those that might have produced any cytotoxic or therapeutic effect. There was evidence of hemolysis at total doses as low as 0.5 mg/kg given intravenously. For man, HAPR is one of the most active hemolytic drugs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0009-9236
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
57-65
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:1122670-Adenosine, pubmed-meshheading:1122670-Adult, pubmed-meshheading:1122670-Bilirubin, pubmed-meshheading:1122670-Blood Cell Count, pubmed-meshheading:1122670-Breast Neoplasms, pubmed-meshheading:1122670-Dipyridamole, pubmed-meshheading:1122670-Erythrocytes, pubmed-meshheading:1122670-Female, pubmed-meshheading:1122670-Hemoglobins, pubmed-meshheading:1122670-Hemolysis, pubmed-meshheading:1122670-Humans, pubmed-meshheading:1122670-Hydroxylamines, pubmed-meshheading:1122670-Male, pubmed-meshheading:1122670-Melanoma, pubmed-meshheading:1122670-Middle Aged, pubmed-meshheading:1122670-Neoplasm Metastasis, pubmed-meshheading:1122670-Neoplasms, pubmed-meshheading:1122670-Purines, pubmed-meshheading:1122670-Rectal Neoplasms, pubmed-meshheading:1122670-Reticulocytes, pubmed-meshheading:1122670-Time Factors
pubmed:year
1975
pubmed:articleTitle
Hemolysis induced by 6-N-hydroxylaminopurine riboside, an adenosine analogue.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.